Please provide your email address to receive an email when new articles are posted on . Of 20 hospitals providing insulin algorithms, 60% stated which patients should initiate basal or nutritional ...

Type 1 diabetes affects 46.3 million people worldwide, and the number of people affected increases by about 3% each year. It requires careful calculations of insulin needs and bothersome daily ...

Closed-loop systems for automated insulin delivery are now the standard of care in type 1 diabetes (T1D) management, helping people living with diabetes better manage their glucose while reducing ...

The Food and Drug Administration has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with Type 1 diabetes. These two devices, along ...

MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning ...

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can help users better manage their type 2 diabetes by recommending insulin-dose ...

Bigfoot Biomedical is doing its part to ensure that the possibility of building a smarter diabetes management system is more than just an urban legend. The tech maker has purchased a new algorithm ...

Hospitalized patients with complex dietary restrictions often develop hyperglycemia, or high blood sugar. This occurs in roughly one-quarter to one-half of these patients and can lead to serious ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...

Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...

Little is known about the comparative vascular safety of basal insulins (intermediate-acting human insulin [IAHI] or long-acting insulin analogue [LAIA]) in type 2 diabetes (T2D). This study sought to ...